ArticleCureus2025
Trends and Clinical Outcomes of Anemia in Women of Reproductive Age: A Retrospective Study Across India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Iron deficiency anemia (IDA) is highly prevalent among women of reproductive age. Despite the wide availability of oral iron formulations, real-world evidence on prescribing practices, treatment outcomes, and patient experiences remains limited. This retrospective, questionnaire-based study evaluated clinical management strategies for anemia in women, focusing on the comparative effectiveness and tolerability of commonly used oral iron salts. Methods This retrospective, multicentric, observational study analyzed anonymized electronic medical records (2018-2024) of anemic women aged 15-49 years across diverse Indian regions. A structured digital questionnaire captured patient-reported symptoms, treatment preferences, and management strategies. The impact of oral iron supplements on hemoglobin, hematocrit, ferritin levels, quality of life, and their associated safety profiles was evaluated. Newer-generation iron formulations were excluded to maintain data uniformity. Results Participants (ages 15-49 years, mean 32.79) were drawn from all major regions of India, providing a geographically diverse representation. Hemoglobin was the main diagnostic criterion (91.01%). Anemia severity was moderate in 46.62%, mild in 44.01%, and severe in 9.37%, with iron deficiency as the leading cause in 95.80% cases. All iron supplements showed significant improvement (all p < 0.001) in hemoglobin, hematocrit, and ferritin. Ferrous fumarate, the most frequently prescribed iron salt, likely due to its high elemental iron content and convenient dosing regimen, demonstrated significant improvement in hemoglobin levels, increasing from 8.67 ± 1.12 to 11.66 ± 1.18 g/dL. The greatest hemoglobin rise was seen with ferrous fumarate (2.99 ± 1.45 g/dL), followed by ferrous sulfate (2.45 ± 1.29), ferrous
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.